# Chimera Clinical Advisory Board Charter

<div align="center">
<img src="https://img.shields.io/badge/-%F0%9F%A7%A0%20CHIMERA%20CLINICAL%20ADVISORY%20BOARD%20%F0%9F%A6%BE-6236FF?style=for-the-badge&labelColor=1A1A2E" alt="Chimera Clinical Advisory Board"/>

**Guiding the Future of Brain-Controlled Exoskeleton Technology**

*Version 1.0 | Effective Date: April 2025*
</div>

## 1. Purpose and Scope

The Chimera Clinical Advisory Board (CAB) serves as an independent body of experts providing strategic guidance, clinical insights, and ethical oversight for the development and implementation of the Chimera brain-controlled exoskeleton platform. The CAB ensures that all clinical aspects of the Chimera project align with best practices in patient care, regulatory requirements, and ethical standards in neurotechnology.

## 2. Responsibilities

### 2.1 Clinical Strategy Development
- Advising on clinical trial design and protocols
- Identifying appropriate patient populations and inclusion/exclusion criteria
- Recommending clinically relevant outcome measures and endpoints
- Guiding development of clinical use cases and therapeutic protocols

### 2.2 Regulatory Guidance
- Providing insights on FDA regulatory pathways and requirements
- Reviewing clinical documentation for regulatory submissions
- Advising on compliance with international medical device regulations (EU MDR, PMDA, etc.)
- Supporting preparation for regulatory meetings and submissions

### 2.3 Safety and Ethics Oversight
- Monitoring and evaluating safety data from clinical studies
- Ensuring ethical considerations are addressed in human-subject research
- Advising on risk management strategies for clinical implementation
- Reviewing adverse event reporting and mitigation strategies

### 2.4 Technology Assessment
- Evaluating clinical utility and effectiveness of the Chimera platform
- Providing feedback on user interface and experience from clinical perspective
- Identifying opportunities for technology improvement based on clinical needs
- Benchmarking against competitive technologies and standard of care

### 2.5 Knowledge Dissemination
- Guiding publication strategy for clinical findings
- Supporting presentations at relevant medical conferences
- Facilitating connections with clinical research networks
- Advising on educational materials for clinicians and patients

## 3. Membership Composition

The CAB consists of 7-9 members representing diverse expertise relevant to brain-controlled exoskeletons:

<table>
<tr>
<th>Expertise Area</th>
<th>Required Experience</th>
<th>Number of Members</th>
</tr>
<tr>
<td><strong>Neurology</strong></td>
<td>
• Expertise in motor neuron diseases, spinal cord injury, or stroke rehabilitation<br>
• Experience with brain-computer interfaces in clinical settings<br>
• Board certification in neurology
</td>
<td align="center">1-2</td>
</tr>
<tr>
<td><strong>Physical Medicine and Rehabilitation</strong></td>
<td>
• Expertise in exoskeleton-assisted rehabilitation<br>
• Experience with mobility assistive technologies<br>
• Board certification in PM&R
</td>
<td align="center">1-2</td>
</tr>
<tr>
<td><strong>Neuroscience/Neurophysiology</strong></td>
<td>
• Expertise in EEG signal processing and interpretation<br>
• Understanding of motor control and neural plasticity<br>
• PhD in neuroscience or related field
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Bioethics</strong></td>
<td>
• Expertise in neuroethics and emerging technologies<br>
• Experience with regulatory ethics committees<br>
• Formal training in bioethics
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Patient Advocacy</strong></td>
<td>
• Representative from relevant patient community<br>
• Experience in patient-centered research design<br>
• Connection to patient advocacy organizations
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Regulatory Affairs</strong></td>
<td>
• Experience with FDA medical device approval processes<br>
• Knowledge of Software as a Medical Device (SaMD) regulations<br>
• RAC certification preferred
</td>
<td align="center">1</td>
</tr>
<tr>
<td><strong>Clinical Research Methodology</strong></td>
<td>
• Expertise in clinical trial design and biostatistics<br>
• Experience with medical device clinical studies<br>
• PhD in biostatistics, epidemiology, or related field
</td>
<td align="center">1</td>
</tr>
</table>

## 4. Appointment and Terms

### 4.1 Selection Process
- Candidates are nominated by Chimera leadership or existing CAB members
- Selection is based on expertise, reputation, and diversity considerations
- Final appointments are approved by the Chimera Board of Directors

### 4.2 Term Length
- Members are appointed for a 2-year term, renewable once
- Initial appointments will be staggered (1-2 years) to ensure continuity
- The CAB Chair is elected by majority vote of members for a 2-year term

### 4.3 Conflict of Interest
- Members must disclose all potential conflicts of interest annually
- Conflicts are reviewed by the Chimera Ethics Committee
- Members with significant conflicts may be recused from specific discussions

## 5. Meetings and Operations

### 5.1 Meeting Frequency
- The CAB meets quarterly at minimum, with additional meetings as needed
- At least two meetings per year must be in-person; others may be virtual
- Emergency meetings may be called by the Chair or Chimera CMO

### 5.2 Meeting Procedures
- Quorum requires attendance of at least 60% of members
- Agenda and materials distributed at least 7 days before meetings
- Meeting minutes and recommendations are documented and distributed to the Chimera leadership team
- Annual review of CAB effectiveness and charter updates as needed

### 5.3 Decision Making
- Recommendations are made by consensus whenever possible
- When voting is necessary, simple majority rules
- Minority opinions are documented in meeting minutes

## 6. Compensation

### 6.1 Honoraria
- Members receive an annual honorarium commensurate with industry standards
- Current rate: $10,000-$15,000 per year, depending on role and responsibilities

### 6.2 Meeting Compensation
- Additional per-meeting compensation: $1,500-$2,500 per in-person meeting
- Virtual meeting compensation: $750-$1,000 per meeting

### 6.3 Expenses
- Travel expenses for in-person meetings are reimbursed
- Members participating in additional activities (e.g., regulatory meetings, site visits) receive additional compensation

## 7. Confidentiality and Intellectual Property

### 7.1 Confidentiality
- All CAB members must sign confidentiality agreements
- Discussions and materials shared with the CAB are considered confidential
- Confidentiality obligations extend 5 years beyond CAB service

### 7.2 Intellectual Property
- Intellectual property developed through CAB activities belongs to Chimera
- Members receive appropriate acknowledgment in patents and publications
- Members waive rights to royalties from IP developed during CAB service

## 8. Current Advisory Board Members

<table>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Expertise</th>
<th>Term</th>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Neurology</td>
<td>2025-2027</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Physical Medicine and Rehabilitation</td>
<td>2025-2027</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Neuroscience</td>
<td>2025-2026</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Bioethics</td>
<td>2025-2026</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Patient Advocacy</td>
<td>2025-2027</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Regulatory Affairs</td>
<td>2025-2026</td>
</tr>
<tr>
<td>[TBD]</td>
<td>[TBD]</td>
<td>Clinical Research Methodology</td>
<td>2025-2027</td>
</tr>
</table>

## 9. Reporting Structure

<div align="center">
<img src="https://mermaid.ink/img/pako:eNptkstOwzAQRX9l5FUr0fADWVRqKxASEt2wYGOcSTLFsYPtFKqq_47zKKjqzuPcc-_YM-EqSMJJRbxDY_GhDXdIVkTxCcl7Z5E8WEdaRXRB65CQvVgVURLyGhWRMaQiXJFV3pGOcBHncR5ncR7_i53vo45wGedxHudxHuf_YhcRXsV5nMd5nMd5nMfY-TnqCNdxHudxHudxHucxdn6LOsK7OI_zOI_zOI_zGDt_RB3hY5zHeZzHeZzHeYydP6OO8CvO4zzO4zzO4zzGzruoI_yJ8ziP8ziP8ziPsfNv1BEe4zzO4zzO4zzOY-w8iTrCU5zHeZzHeZzHeYyd0whPcR7ncR7ncR7nMXbOIjzFeZzHeZzHeZzH2DmP8BTncR7ncR7ncR5j5yLCU5zHeZzHeZzHeYydy" alt="Reporting Structure" width="500px" />
</div>

The CAB reports directly to the Chief Medical Officer and provides regular updates to the Chimera Executive Leadership Team. The CAB Chair presents formal recommendations to the Board of Directors annually.

## 10. Amendment Process

This charter may be amended by a two-thirds vote of the CAB membership, subject to approval by the Chimera Board of Directors. The charter will be reviewed annually to ensure alignment with industry best practices and Chimera's evolving needs.

---

<div align="center">
<p><em>This charter was established on April 16, 2025 and last updated on April 16, 2025.</em></p>

<p><strong>Contact:</strong> <a href="mailto:clinical-advisory@chimera-bci.org">clinical-advisory@chimera-bci.org</a></p>

<p>
<img src="https://img.shields.io/badge/FDA-Compliance%20Ready-green?style=flat-square&logo=data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgMCAyNCAyNCI+PHBhdGggZD0iTTEyIDJDNi41IDIgMiA2LjUgMiAxMnM0LjUgMTAgMTAgMTAgMTAtNC41IDEwLTEwUzE3LjUgMiAxMiAyem0tMSAxNkg3di0yaDR2MnptNi40LTRINi42Yy0uOSAwLTEuNi0uNy0xLjYtMS42VjYuNkM1IDUuNyA1LjcgNSA2LjYgNWgxMC44Yy45IDAgMS42LjcgMS42IDEuNnY1LjhjMCAuOS0uNyAxLjYtMS42IDEuNnoiIGZpbGw9IndoaXRlIi8+PC9zdmc+" alt="FDA Compliance Ready">
<img src="https://img.shields.io/badge/ISO%2014155-Clinical%20Investigation-blue?style=flat-square" alt="ISO 14155 Compliant">
<img src="https://img.shields.io/badge/21%20CFR%20Part%2011-Compliant-blue?style=flat-square" alt="21 CFR Part 11 Compliant">
</p>
</div>
